Page last updated: 2024-12-06
glisentide
Description
Glisentide is a novel synthetic peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R). It is being investigated as a potential treatment for type 2 diabetes. Glisentide has been shown to stimulate insulin secretion, suppress glucagon secretion, and slow gastric emptying. In clinical trials, glisentide has demonstrated significant improvements in glycemic control in patients with type 2 diabetes. The synthesis of glisentide involves the use of solid-phase peptide synthesis techniques. Glisentide is studied because it is a promising new treatment option for type 2 diabetes, offering several potential benefits over existing therapies. These benefits include improved efficacy, fewer side effects, and a more convenient dosing schedule. Glisentide is being investigated for its potential to treat type 2 diabetes. It is a synthetic peptide that acts as an agonist of the GLP-1 receptor. Glisentide has shown promising results in clinical trials, with significant improvements in glycemic control. The compound's effects include increased insulin secretion, reduced glucagon secretion, and slowed gastric emptying. Glisentide's importance lies in its potential to offer a new and effective treatment option for type 2 diabetes.'
glisentide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 65779 |
| CHEMBL ID | 2105089 |
| CHEBI ID | 135725 |
| SCHEMBL ID | 37753 |
| SCHEMBL ID | 20657516 |
| MeSH ID | M0353033 |
Synonyms (36)
| Synonym |
|---|
| glisentide |
| staticum (tn) |
| glypentide |
| glisentide (inn) |
| 32797-92-5 |
| D02428 |
| CHEBI:135725 |
| n-[2-[4-(cyclopentylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide |
| glipentidum |
| ur-661 |
| staticum |
| glisentida [inn-spanish] |
| n-(4-(beta-o-anisamidoethyl)benzenesulfonyl)-n'-cyclopentylcarbamide |
| 392tql1e2z , |
| unii-392tql1e2z |
| glipentidum [inn-latin] |
| glipentida |
| glisentidum [latin] |
| glisentida [spanish] |
| glisentidum [inn-latin] |
| einecs 251-226-3 |
| n-(2-(4-((((cyclopentylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide |
| glisentida |
| glisentidum |
| glipentide |
| glipentida [inn-spanish] |
| 1-cyclopentyl-3-((p-(2-(o-anisamido)ethyl)phenyl)sulfonyl)urea |
| glisentide [inn] |
| CHEMBL2105089 |
| glisentide [who-dd] |
| glisentide [mart.] |
| SCHEMBL37753 |
| DTXSID10186465 |
| SCHEMBL20657516 |
| glisentide;staticum;ur661; |
| Q27256848 |
Drug Classes (1)
| Class | Description |
|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.32
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.32 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.40 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |